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Recent genomic data indicate that RNA polymerase II (Pol II) function extends beyond conventional transcription of
primarily protein-coding genes. Among the five snRNAs required for pre-mRNA splicing, only the U6 snRNA is
synthesized by RNA polymerase III (Pol III). Here we address the question of how Pol II coordinates the expression of
spliceosome components, including U6. We used chromatin immunoprecipitation (ChIP) and high-resolution mapping
by PCR to localize both Pol II and Pol III to snRNA gene regions. We report the surprising finding that Pol II is highly
concentrated ;300 bp upstream of all five active human U6 genes in vivo. The U6 snRNA, an essential component of
the spliceosome, is synthesized by Pol III, whereas all other spliceosomal snRNAs are Pol II transcripts. Accordingly, U6
transcripts were terminated in a Pol III-specific manner, and Pol III localized to the transcribed gene regions. However,
synthesis of both U6 and U2 snRNAs was a-amanitin-sensitive, indicating a requirement for Pol II activity in the
expression of both snRNAs. Moreover, both Pol II and histone tail acetylation marks were lost from U6 promoters upon
a-amanitin treatment. The results indicate that Pol II is concentrated at specific genomic regions from which it can
regulate Pol III activity by a general mechanism. Consequently, Pol II coordinates expression of all RNA and protein
components of the spliceosome.
Citation: Listerman I, Bledau AS, Grishina I, Neugebauer KM (2007) Extragenic accumulation of RNA polymerase II enhances transcription by RNA polymerase III. PLoS Genet
3(11): e212. doi:10.1371/journal.pgen.0030212
Introduction
The spliceosome is a multicomponent complex of five small
nuclear RNAs (snRNAs) and ;250 proteins that assemble on
pre-mRNA to catalyze intron removal [1]. U6 snRNA is the
shortest and least variable of the spliceosomal snRNAs,
reflecting its central role in the splicing process [2]. It is a
very dynamic molecule undergoing multiple conformational
changes during assembly and splicing. Together with Lsm
proteins and Prp24, U6 snRNA forms the U6 small nuclear
ribonucleoparticle (snRNP) and is also found base paired with
U4 snRNA in the U4/U6 di-snRNP and in the U4/U6U5 tri-
snRNP [3,4]. U6 snRNA is an exceptional member of the
spliceosomal snRNAs. While U1, U2, U4, and U5 snRNAs are
synthesized by RNA polymerase II (Pol II) and contain a 2,2,7-
trimethylguanosine (TMG) cap at their 59 ends, U6 snRNA is
synthesized by RNA polymerase III (Pol III) and contains a c-
monomethyl phosphate cap. Furthermore, the U6 snRNA 39
end is posttranscriptionally uridylated and blocked with a
29,39-cyclic phosphate [5–8]. These features are shared among
some Pol III transcribed snRNAs, such as 7SK and H1. Direct
evidence that the U6 snRNA gene is transcribed by Pol III
relies upon its a-amanitin insensitivity in vitro. U6 snRNA
gene transcription in S100 extracts and isolated nuclei was
not sensitive to low a-amanitin concentrations that selectively
inhibit Pol II but not Pol III. Furthermore, a cloned human
U6 snRNA gene could be transcribed in a HeLa S100 extract
lacking Pol II activity [5,8]. Pol III transcription of U6 snRNA
genes was reported to occur in Xenopus tropicalis oocytes,
Saccharomyces cerevisiae and Schizosaccharomyces pombe [9–12].
Other evidence for Pol III-directed U6 snRNA gene tran-
scription is the fact that the gene ends with a stretch of five
thymidine residues, a common Pol III transcription termi-
nation site [13,14].
The snRNA genes are highly interesting because they have
very similar promoters yet are transcribed by two different
polymerases [15]. All vertebrate snRNA gene promoters
contain a distal sequence element (DSE) ;220 bp upstream
of the initiation site that functions as an enhancer and a
proximal sequence element (PSE) 60 bp that is a core
promoter element. The PSE and DSE recruit the same set of
transcription factors to the different snRNA genes. The
snRNA activator protein complex (SNAPc) binds to the PSE
and nucleates the assembly of the transcription initiation
complex, whereas the DSE contains OCT and SPH elements
that serve as binding sites for Oct-1 and Staf transcription
factors. A special feature of the U6 snRNA promoter is the
presence of a TATA box at 25 bp, which binds TBP in the
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TFIIIB complex and leads to recruitment of Pol III [16]. The
U6 promoter can drive transcription by Pol II under certain
circumstances, such as mutation in the U6 snRNA gene TATA
box; conversely, insertion of a TATA box into the U2 snRNA
promoter converts this Pol II promoter into a template for
Pol III [9,17–19]. Thus, the TATA box, present in all identified
human U6 genes, is responsible for the Pol III specificity of
the U6 snRNA promoters [20,21].
The expectation generated by these mechanistic studies is
that Pol III—not Pol II—will be recruited to active U6 genes.
Yet, here we show that the Pol II large subunit is highly
concentrated close to the DSE ;300 bp upstream of the
transcription start sites in all five known active U6 loci in
vivo. Further experiments indicate that the Pol II present at
U6 promoters plays a positive role in the synthesis of U6
snRNA by Pol III, without affecting Pol III recruitment.
Results
Pol II and Pol III Accumulate in Distinct Peaks at U6 snRNA
Gene Promoters In Vivo
Human U6 snRNA is expressed from several genes, five of
which have been identified so far. Four apparently inactive
U6 genes are also present in the genome [22]. Using
chromatin immunoprecipitation (ChIP), we detected robust
accumulation of Pol III at promoters of the active U6 snRNA
genes (U6–1, U6–2, U6–7, U6–8 and U6–9) but not at the
promoters of the inactive genes (U6–3, U6–4 and U6–6) in
HeLa cells (Figure 1A). As expected, Pol III levels on the
active U6 and tRNALeu genes were comparable. Interestingly,
the U6–7 promoter, which exhibits the weakest Pol III
occupancy, contains a suboptimal PSE and was shown to be
transcriptionally less active in vivo compared to other U6
snRNA genes [22]. Thus, the extent of Pol III accumulation on
the nine U6 genes correlates with their transcriptional
activity.
Unexpectedly, when we performed ChIP with a Pol II-
specific antibody, we detected robust Pol II accumulation at
all active U6 gene promoters but not on the inactive ones
(Figure 1B). The extent of Pol II occupancy on the various U6
promoters was comparable to the highly active phosphoglycerate
kinase (PGK1) gene promoter. To examine the genomic
regions surrounding the U6 genes, we consulted the UCSC
human genome browser [23,24]. Start sites of protein coding
genes mapped close to U6–9 and U6–2 and were shown to be
transcriptionally active (Figure S1 and unpublished data);
consequently, the Pol II signals on the U6–2 and U6–9
promoters might be partly derived from these Pol II genes. In
contrast, the only neighboring gene of U6–1 (BC033162, ;1
kb downstream of the U6–1 transcription start site) was
transcriptionally inactive (Figure S2A). Furthermore, no
transcripts derived from sequences 800 bp upstream or
downstream of U6–1 were detected by Northern blotting with
probes covering the þ and  strands (Figure S2B). No genes
were annotated near the active U6–7 and U6–8 genes, which
lie 1 kb apart from each other on opposite strands of
chromosome 14 (Figure S1). This indicates that Pol II
accumulation on U6–1, U6–7 and U6–8 snRNA gene pro-
moters is not due to the presence of neighboring Pol II
promoters. Therefore, all subsequent experiments focus on
these three U6 genes. The high levels of Pol II occupancy on
U6 promoters and the observation that both polymerases are
present only on active U6 gene promoters suggest that both
polymerases may have a function in U6 gene expression and
ultimately spliceosome regulation.
To further investigate this unforeseen behavior of Pol II,
the accumulation pattern of the two polymerases was mapped
in greater detail on the U6–1, U6–7, and U6–8 gene regions by
Figure 1. Both Pol II and Pol III Accumulate at Active U6 snRNA Gene
Promoters
Sheared chromatin from pemHeLa cells that had been crosslinked with
formaldehyde was immunoprecipitated with (A) anti-Pol III (1900) or (B)
anti-Pol II antibodies (8WG16). DNA was purified following reversal of
crosslinks. qPCR primers specific for regions ; 300 bp upstream of active
and inactive U6 genes (U6–1, U6–2, U6–7, U6–8, U6–9 and U6–3, U6–4,
U6–6, respectively), PGK1, and tRNALeu genes (Pol II and Pol III controls,
respectively). All values are relative to nonimmune IgG and normalized to
an intergenic control region. Error bars represent the SEM of at least
three independent experiments.
doi:10.1371/journal.pgen.0030212.g001
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Author Summary
During transcription, RNA polymerases synthesize an RNA copy of a
given gene. Human genes are transcribed by either RNA polymerase
I, II, or III. Here, we focus on transcription of the U6 gene that
encodes a small nuclear RNA (snRNA), a non-coding RNA with
unique activities in gene expression. The U6 snRNA is transcribed by
RNA polymerase III (Pol III); here we report the surprising finding
that RNA polymerase II (Pol II) is important for efficient expression of
the U6 snRNA. Interestingly, high concentrations of Pol II have been
recently observed on genomic regions that are considered outside
of transcribed genes. We localized Pol II to a region upstream of the
U6 snRNA gene promoters in living cells. Inhibition of Pol II activity
decreased U6 snRNA synthesis and was accompanied by a decrease
in Pol II accumulation as well as transcription-activating histone
modifications, while Pol III remained bound at U6 genes. Thus, Pol II
may promote U6 snRNA transcription by facilitating open chromatin
formation. Our results provide insight into the extragenic function of
Pol II, which can coordinate the expression of all components of the
RNA splicing machinery, including U6 snRNA.
ChIP. Strikingly, Pol II and Pol III accumulate in two distinct
peaks on each of these three U6 genes. Pol II is highly
enriched 300–700 bp upstream of the transcription start site,
whereas Pol III is most highly enriched over the U6 snRNA
transcribed region (Figure 2A–2D and Figure S3). For Pol II
ChIPs, we made use of two different, well-characterized
antibodies that recognize either total Pol II (4H8, Figure S3 C,
D) or the hypophosphorylated heptad repeat of the Pol II
CTD (8WG16, Figure S3 E, F); both antibodies revealed Pol II
accumulation in the same pattern on the U6 gene promoter.
Interestingly, Pol II occupies the region around the DSE that
functions as an enhancer for snRNA transcription [25]. The
sharp separation of Pol II and Pol III crosslinking signals
indicates that Pol II and Pol III bind to distinct sequences in
the U6 promoter regions.
Comparison of the Pol II distribution at the U1 and U6
snRNA genes suggests that Pol III transcribes the U6 genes
examined. Both U1 and U6 promoters contain the DSE at
approximately220 bp and the PSE at60 bp. However, the
U1 promoter lacks a TATA box and is transcribed by Pol II.
As shown in Figure 3, Pol II is massively detectable on the U1
snRNA transcribed region, thus resembling the accumulation
pattern of Pol III on U6 transcribed regions. Note that the Pol
II peak at the U1 gene promoter is very broad and
encompasses the distal region; thus, Pol II is enriched
approximately 30-fold above background near the DSEs of
both U1 and U6 genes, suggesting that Pol II transcription
complexes upstream of the transcription start site may play a
role in the expression of all snRNA genes.
Phosphorylation of the Pol II C-terminal domain (CTD) is
associated with transcriptional initiation and elongation
activity [26]. Phosphorylated Serine 5 (Ser5) residues asso-
ciated with initiation are most highly detectable in promoter-
proximal regions [27]. A specific antibody (H14) for this CTD
modification has been previously generated and character-
ized [28,29]. ChIP with H14 revealed that Pol II CTD on the
U6–1 promoter is phosphorylated, indicating that an active
Pol II transcription complex may form upstream of the
natural U6 transcription start site (Figure S4).
Pol II Activity Is Required for Proper U6 snRNA Expression
In Vivo
To investigate whether transcriptionally active Pol II plays
a functional role in U6 snRNA biogenesis in vivo, we made
use of the drug a-amanitin that specifically inhibits Pol II at
low concentrations [30]. Structural and biochemical studies
indicate that a-amanitin inhibits Pol II translocation along
the DNA [31,32]. As the U6 snRNA is extremely stable with a
half-life of at least 24 h [33], metabolic labeling was used to
detect U6 snRNAs synthesized in the presence or absence of
a-amanitin. Hybrid selection of endogenous U6 and U2
snRNA, 5S rRNA and plasmid-derived tRNAArg revealed
distinct effects of a-amanitin on their expression. Figure 4
shows that the Pol III-driven genes 5S and tRNA were
relatively unaffected by a-amanitin treatment, whereas both
U2 and U6 snRNA levels were strongly reduced. Band
intensities were normalized to 5S rRNA that served as an
internal loading control. Quantification of three independent
experiments showed that tRNA levels remained virtually
constant after a-amanitin treatment (the mean 6 standard
error of the mean (SEM) ¼ 84% 6 18% of the RNA
remaining). In contrast, only 10% 6 2% of U2 snRNA and
Figure 2. Pol II and Pol III Accumulate in Two Distinct Peaks at the U6–1, U6–7, and U6–8 Promoters
(A, B) Diagrams of the U6–1 and U6–7/U6–8 gene regions, with black lines specifying the PCR amplicons identified by the central nucleotide. Boxes
represent the position of the DSE. (C, D) Summary plots of ChIP experiments with Pol II and Pol III distributions on U6–1 gene region (C) and U6–7 and
U6–8 (D). Crosslinked pemHeLa extracts were used for ChIP with primers amplifying fragments distributed 1 kb upstream and downstream of each
gene. Antibodies specific for Pol II (4H8) and Pol III were used. X-axis values in (C) are relative to the U6–1 transcription start site at positionþ1, whereas
transcription start sites in (D) are atþ1,302 (U6–7) andþ2,426 (U6–8), relative to an arbitrary point upstream of U6–7. Data points are placed according
to the center positions of the PCR products along the region. The peak value for the region (either U6–1 region or U6–7/U6–8 region) was determined
for each biological replicate and set to 100%; displayed values are averaged among at least three biological replicates. Error bars represent the SEM.
doi:10.1371/journal.pgen.0030212.g002
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48% 6 3% of U6 snRNA remained compared to untreated
cells. Unpublished work from our lab showed that labeled U6
snRNA assembles with U6 and U4/U6 snRNP-specific proteins
under conditions of a-amanitin treatment (data not shown),
suggesting that U6 levels were not diminished due to a lack of
sufficient snRNP proteins. This surprising result indicates
that Pol II activity is required for full expression levels of
endogenous U6 snRNA in vivo.
Although nine U6 genes have been identified in the human
genome and their promoters studied [22], it is unclear how
many U6 genes might be present and contribute to the U6
species measured in the above metabolic labeling experiment.
In order to specifically determine the action of a-amanitin-
mediated Pol II inhibition on individual U6 snRNAs in their
natural promoter context, we made use of plasmids harbor-
ing U6 maxigenes with a 9 bp insert at the 39 end of the
transcribed region and the genomic 59 and 39 flanking regions
including all regulatory sequences [22]. The 9 bp insert serves
as a primer-binding site for reverse transcription and for
subsequent quantitative PCR (qPCR) for exclusive detection
of the plasmid-derived U6 snRNA. After a-amanitin treat-
ment, the expression of U6–9, U6–1 and U6–8 maxigenes was
severely decreased to 18%, 12% and 4% of controls,
respectively (Figure 5). The endogenous Pol III transcripts,
5S rRNA and pre-tRNATyr, were largely unaffected; as an
additional control, transfection and expression of tRNAArg
from a plasmid was also unaffected by a-amanitin (see Figure
4). Note that the failure of a U6–4 maxigene to be transcribed
[22] demonstrates that a-amanitin-sensitive transcription is
specifically driven by the U6 promoters and not a background
activity of the plasmid backbone. The drastic down-regu-
lation of the U6 maxigenes driven by their endogenous
promoters clearly indicates that Pol II is required for
expression of these genes.
Role of Pol II in Pol III Transcription of U6 Genes
One possible explanation for the above results is that Pol II
might actually transcribe U6 snRNA genes. Previous work has
shown that Pol II can transcribe from U6 snRNA promoters in
human nuclear extracts and Xenopus oocytes [9,17,18].
Furthermore, human U6 promoters used in short hairpin
constructs can drive expression of luciferase and green
Figure 4. a-Amanitin Reduces Endogenous U6 snRNA Expression
HeLa cells were transfected with a tRNAArg maxigene and 16 h later
treated with 10 lg/ml a-amanitin or left untreated. After 3 h, 250 lCi
[32P] orthophosphate was added to the medium for 6 h. Total RNA was
collected and 5S rRNA along with tRNAArg, U2 and U6 snRNAs were
hybrid selected with biotinylated complementary oligos. Hybrid-selected
RNA was separated on a denaturating polyacrylamide gel and exposed
to PhosphorImager plates. The 5S rRNA bands served as a loading
control. Three biological replicates were analyzed and a representative
gel is shown.
doi:10.1371/journal.pgen.0030212.g004
Figure 3. Comparison of Pol II Accumulation Pattern on U6–1 and U1
snRNA Genes
ChIP with Pol II mAb 4H8 was performed with pemHeLa crosslinked
extracts and the purified DNA subjected to qPCR with primers along the
U6–1 and U1 snRNA gene regions as shown (Ensembl ID
ENSG00000194297 on chromosome 1). Data points represent the center
point of the amplified region and Pol II fold accumulation over
background and intergenic region, as in Figure 1. Diagrams below the
plot indicate the features of both genes, which have been aligned at
their respective transcription start sites (arrows). Error bars represent the
SEM of at least three independent experiments.
doi:10.1371/journal.pgen.0030212.g003
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fluorescent protein (GFP) [19]. In order to identify the
polymerase responsible for actual U6 snRNA transcription,
we designed U6 maxigenes that harbor an additional insert
midway through the transcribed region; this was used for
specific primer extension analysis and was followed by a Pol
III termination signal of five thymidine residues (see Figure
6). If Pol II transcribes the U6 maxigene, transcription should
not terminate at the early Pol III termination signal. If Pol III
transcribes the maxigene, termination is expected to occur at
the introduced termination site [13,14]. As shown in Figure 6,
the short U6 snRNA transcript, but not the full-length
transcript, was detected, strongly indicating that the U6
maxigene is transcribed by Pol III. Note that the short,
prematurely terminated U6 transcript was less abundant than
the transcript generated from the control maxigene. Most
likely this is because U6 snRNA stability requires 39 end
binding sites for processing factors and snRNP components
(Lsm proteins) that are downstream of the inserted termi-
nation site [3,4]. Because Pol II activity was required for
maxigene transcription (see Figure 5), it appears that Pol II
controls U6 gene transcription by Pol III.
To gain insight into how Pol II might influence Pol III-
mediated U6 gene expression, the effect of a-amanitin
treatment on Pol II and Pol III distributions was examined.
We performed ChIP on cells treated with a-amanitin as
described in Figure 4. Pol III distribution on U6–7 and U6–8
was nearly unchanged (Figure 7B), whereas Pol II occupancy
at the promoter was decreased to 50% after a-amanitin
treatment (Figure 7A). These data indicate that Pol II is not
required for the steady-state accumulation of Pol III at the U6
promoter. Interestingly, a ;50% reduction of U6 snRNA
synthesis is observed under the same a-amanitin treatment
conditions (see Figure 4), strongly arguing for a functional
link between Pol II occupancy and U6 snRNA expression
levels. The observations that Pol III occupancy does not
change upon loss of Pol II and that Pol II is not involved in
the actual transcription of U6 snRNA suggest that Pol II has a
role in the regulation of Pol III activity.
Transcriptionally active Pol II genes are characterized by
specific histone modifications, most prominently acetylation
[26,34]. It is not well understood how chromatin at Pol III
genes is modified; however, it was shown that histone H4 is
acetylated at active U6 genes [22]. Because Pol II may target
histone modifying enzymes to chromatin [26,35,36], we tested
whether histone H4 acetylation was affected by a-amanitin
treatment. In the absence of a-amanitin, histone H4
acetylation was highest in the U6–7 and U6–8 promoter
regions and less pronounced at the U6 transcribed region,
although still above background. Interestingly, after a-
amanitin treatment, histone H4 acetylation in the promoter
Figure 5. Low a-Amanitin Concentrations Inhibit U6 snRNA Maxigene
Expression
HeLa cells were transiently transfected with 1 lg U6–1, U6–8, and U6–9
maxigenes carrying a 9 bp insertion and treated simultaneously with 50
nM a-amanitin oleate for 20 h or left untreated. Expression of U6
maxigenes, LDHA, 28S rRNA, 5S rRNA and pre-tRNATyr was measured by
gene-specific reverse transcription, followed by conventional PCR and
agarose gel electrophoresis (A) or qPCR (B). qPCR values were normalized
to 28S rRNA and expression levels are expressed relative to untreated
controls. Error bars represent the SEM. The data represents the average
of at least three independent experiments.
doi:10.1371/journal.pgen.0030212.g005
Figure 6. Pol III Transcribes U6–1 Maxigene
Primer extension analysis of RNA from HeLa cells cotransfected with GFP
expression plasmid and U6–1 maxigene. (A) Design of the two U6–1
maxigenes with insertions atþ66 andþ87 bp (white boxes) to allow for
maxigene-specific reverse transcription. Construct ‘‘U6–1 maxiT’’ harbors
five thymidine residues directly downstream of the linker insertion; ‘‘U6–
1 MaxiC’’ harbors the same primer binding site but lacks the T’s. The
cross-hatched box represents the reverse primer specific for the
downstream insertion, yielding extension products of either 114 bp
(U6–1 maxiT) or 109 bp (U6–1 maxiC). Grey filled box and black filled box
represent reverse primers specific for upstream insertion with or without
T residues, respectively, leading to extension products of 83 bp (U6–1
maxiT) or 79 bp (U6–1 maxiC). Primer extension of mRNA derived from
cotransfected GFP plasmid yields a 158 bp product. Primer extension
products were separated on a denaturing polyacrylamide gel and
exposed on a PhosphorImager. (B) A representative gel is shown.
doi:10.1371/journal.pgen.0030212.g006
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region of U6–8 was dramatically reduced (Figure 7C). At the
PGK1 promoter, a-amanitin also decreased Pol II levels, while
Pol III levels at the tRNALeu promoter were unaffected (data
not shown). Thus, at this U6 promoter, a-amanitin treatment
led to a concomitant loss of Pol II and histone modifications
associated with transcriptional activity and chromatin open
state. These data suggest that Pol II-mediated histone
modifications may positively regulate Pol III transcription
of U6 snRNA genes.
Discussion
Genome-wide studies in yeast, mouse, and human cells have
demonstrated that RNA polymerase II is not only associated
with active or even inactive but well-annotated protein-
coding genes [37,38]. Instead, many Pol II transcripts derive
from intergenic regions [39], implying that Pol II is
distributed throughout the genome at unexpected sites.
Indeed, Pol II is enriched at many untranscribed genes in
budding yeast [40] and quite dramatically at promoters of
inactive genes in human ES cells [41]. In contrast, recruitment
of the Pol III transcriptional machinery seems confined to
known Pol III-driven genes and to reflect transcriptional
activity, at least in yeast [42]. The present study documents
the unanticipated location and function of RNA Pol II at Pol
III transcription units, providing insights into the potential
activities of Pol II elsewhere in the genome.
Surprisingly little is known about Pol III structure,
function, or regulation [43–45]. The realization that Pol III
activity can be regulated by trans-acting factors (e.g., c-myc,
p53, Rb, Maf1) indicates that regulation of Pol III activity may
be more complex than anticipated and that Pol II and Pol III
regulatory mechanisms may be shared [46–50]. Another
transcription regulatory mechanism that may be general to
both polymerases is histone tail modification. Indeed, histone
acetylation was found to dramatically increase transcription
by Pol III in vitro [51]. Based on the evidence summarized
below, we speculate that Pol II recruitment upstream of the
U6 transcription start site leads to the opening or remodeling
of chromatin, thus facilitating Pol III initiation or elongation.
First, our data are consistent with the conclusion that Pol
III transcribes the U6 snRNA genes. Both Pol II and Pol III are
recruited to all active U6 genes; however, Pol II is present on
upstream promoter elements and not on transcribed regions.
In contrast, Pol III is concentrated on the coding regions,
strongly suggesting that Pol III is engaged in U6 transcription.
Moreover, the introduction of an early Pol III termination
site into a U6 maxigene led to premature termination of the
transcript at the expected site, and longer transcripts
indicative of Pol II mediated elongation past the introduced
Pol III termination site were not detected. We were also
unable to detect capped or longer forms of U6 snRNA that
Figure 7. Pol II and Histone Acetylation Levels at U6 Genes Are Reduced
by a-Amanitin
Extracts from crosslinked Hela cells, either treated for 9 h with 10 lg/ml
a-amanitin or left untreated, were subjected to ChIP with (A) Pol II, (B) Pol
III, or (C) acetylated histone H4 antibodies. Purified DNA was subjected to
qPCR with primers along U6–7 and U6–8 gene regions. All values are
relative to background and normalized to an intergenic control region.
Error bars represent the SEM. The data represents the average of three to
five independent experiments.
doi:10.1371/journal.pgen.0030212.g007
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might have been transcribed by Pol II initiating from an
alternative upstream promoter (IL&KN, unpublished data).
Therefore, all of the available evidence indicates that U6
snRNA is synthesized by Pol III.
Second, we gathered compelling evidence that Pol II
accumulation, and possibly activity, is essential for proper
U6 snRNA expression. As detected by ChIP, Pol II large
subunit is as abundant on the promoters of active U6 genes as
it is on highly expressed bona fide Pol II-driven genes. Pol II
does not accumulate on inactive U6 genes, linking transcrip-
tional activity and Pol II occupancy. The transcription
inhibitor a-amanitin binds to Pol II with high affinity and
blocks its translocation on the DNA template [31,32]. We
showed that individual, plasmid-borne U6 snRNA genes are
highly a-amanitin sensitive, indicating that Pol II activity is
required for U6 gene expression. Importantly, a-amanitin
strongly reduced endogenous U2 and U6 snRNA synthesis
whereas 5S rRNA and tRNA levels remained constant under
the same conditions. The latter observation makes it unlikely
that decreased expression of specific transcription factors
upon a-amanitin treatment accounts for the observed effects
on U6 transcription. The fact that Ser5 phosphorylation of
the Pol II CTD was detected in the U6–1 promoter region
underscores the suggestion that Pol II may be transcription-
ally active upstream of the U6 transcriptional start site (see
Figure S4). If so, Pol II likely synthesizes either very short and/
or very unstable RNAs from this upstream position, because
we were unable to detect transcripts derived from either
strand (see Figure S2B).
Finally, a-amanitin treatment led to the loss of Pol II as well
as histone H4 acetylation levels at the U6–8 promoter.
Histone acetylation is thought to maintain the unfolded
structure of transcriptionally active chromatin [52]. Interest-
ingly, at least two bona fide histone acetyltransferases
associate with elongating Pol II [35,36], implying that Pol II
can distribute acetylation marks along transcribed chromatin
[53]. We speculate that Pol II recruitment to U6 genes may
direct activating histone modifications to U6 promoters and
thereby promote Pol III activity at U6 loci. This hypothesis
might explain the discrepancy between our in vivo data and
the a-amanitin insensitivity of U6 transcription from plas-
mids in vitro. In vivo, access to upstream promoter regions
might be constrained by nucleosomal packaging, and the
concomitant action of Pol II and histone acetyltransferases
could facilitate the opening of chromatin and binding of
factors relevant for Pol III initiation. Indeed, the presence of
positioned nucleosome between the DSE and PSE may
facilitate regulation of Pol III by Pol II via histone tail
modification [54,55].
We considered the possibility that Pol II is required co- or
post-transcriptionally for U6 snRNA expression. Pol II could
be responsible for recruitment of U6 snRNA processing
factors, such as U6 capping enzymes, La protein, 39 nuclease,
cyclic phosphatase, or uridyl transferase [6,7,56–59]. Recruit-
ment of these factors, though so far not linked to Pol II in any
way, could theoretically promote U6 snRNA processing and/
or stability. However, metabolically labeled U6 snRNA does
assemble with U6 and U4/U6 snRNP specific proteins under
conditions of a-amanitin treatment (I.L. and K.M.N., unpub-
lished results), suggesting that U6 snRNP proteins are not
limiting. Consistent with this, U6 snRNA stability is not
compromised by translational inhibitors [60]. Finally, U6
snRNP stability is not likely dependent on U4 snRNA
expression, because the ratio of U4 and U6 snRNAs varies
widely among cell types [61–63]. Taken together, we have no
reason to suspect that U6 snRNP stability might be a factor.
The broader consequences of these findings are that two
RNA polymerases seem to cooperate to express proper levels
of the RNA and protein components of the spliceosome. This
is reminiscent of the observation that the production of the
ribosome—a distinct RNA–protein machine that requires the
activities of Pols I, II, and III must be coordinated as cells
grow and divide. Indeed, recent evidence suggests that RNA
polymerase I (Pol I) activity controls synthesis of ribosomal
protein and 5S rRNA genes by Pols II and III [64]. In another
example, the human protein Maf1 negatively regulates Pols I,
II, and III-dependent transcription [47,48]. Our study also
suggests that polymerase cooperation is likely a factor when
short hairpin RNAs (shRNAs) are expressed under the control
of the U6 promoter for the purpose of RNA interference.
Interestingly, spliceosomal snRNA levels vary considerably
with respect to one another. For example, U1 and U2 snRNAs
are 5- to 10-fold more abundant than U4, U5, and U6 snRNAs
in tissue culture cells [62]. Presumably this balance of
spliceosomal components is optimal to support spliceosome
assembly, splicing, and recycling of spliceosomal components.
Undeniably, production of the U6 snRNP alone requires
products of Pol II (e.g., La, SART3/p110, and Lsm proteins) as
well as Pol III (U6 snRNA). The data presented here clearly
demonstrate that Pol II activity controls all aspects of
spliceosomal snRNP biogenesis.
Materials and Methods
Cell culture. Hela and pemHeLa cells were grown in DMEM
(Gibco) supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Gibco). The pemHeLa cell line is a variant
of standard HeLa cells; it contains the rat pem homeobox gene stably
integrated [65] and grows to a high density favourable for ChIP.
Standard HeLa cells were used for all experiments involving
transfection.
Chromatin immunoprecipitation and real time PCR. A modifica-
tion of the technique described by Kuo et al. was used [66]. Briefly,
108 pemHeLa or HeLa cells were grown for 9 h 6 10 lg/ml a-
amanitin before crosslinking with 1% formaldehyde (final concen-
tration) added directly to the medium. Cells were washed with PBS
and collected. Cell pellets were resuspended in 2 ml SDS lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1) containing
complete protease inhibitor cocktail (Roche) and incubated for 10
min on ice. Cell extracts were sonicated with a Branson sonifier W-
450 D at 30% amplitude with 15310 s bursts resulting in 200–500 bp
chromatin fragments and then centrifuged for 10 min at 14,000 rpm.
A 200 ll aliquot of the extract was diluted 1:10 in ChIP dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl,
pH 8.1, 167 mM NaCl) containing protease inhibitors. The chromatin
solution was pre-cleared at 4 8C with sepharose beads for 1 h before
overnight incubation (4 8C) with either (1) 10 lg of 8WG16
(Neoclone), (2) 5 lg of 4H8 recognizing both Pol II0 and Pol IIA
(Abcam), (3) 4 ll of rabbit polyclonal anti-RNA Pol III 1900 directed
against the RPC 155 subunit of human Pol III (a gift from Robert J.
White, [67]), (4) 4 ll of anti-acetyl-histone H4 (Upstate), or (5) 10 lg of
non-immune IgG (Sigma) as control. Complexes were immunopreci-
pitated with GammaBind G sepharose beads (Pharmacia Biotech) for
1 h at 4 8C. The beads were washed rocking for 4 min in each of the
following buffers: Low Salt Immune Complex Wash Buffer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150
mM NaCl), High Salt Immune Complex Wash Buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl),
LiCl Immune Complex Wash Buffer (0.25 M LiCl, 1% NP-40, 1%
deoxycholic acid, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1) and twice in
TE. The immune complexes were eluted in 1 % SDS and 50 mM
NaHCO3 and crosslinks were reversed for 6 h at 65 8C. Samples were
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digested with proteinase K for 1 h at 45 8C and the DNA extracted
with the Qiagen PCR purification kit.
DNA templates retrieved by ChIP were analyzed by qPCR on a
Stratagene MX3000, using the SYBR Green method (ABsolute QPCR
SYBR Green Rox Mix, AB Gene). The reaction volume was 20 ll, with
4 ll DNA template and 90–900 nM of each primer according to
individual optimization. Primer sets distinguishing between different
regions of the genes were designed by using the Primer3 program
(http://fokker.wi.mit.edu/primer3/input.htm) and are available upon
request. They were blasted against the human genome to verify their
specificity. Moreover, primer sets were evaluated by conventional
and qPCR to ensure that only uniformly sized products were
amplified.
The relative proportions of coimmunoprecipitated gene fragments
were determined based on the threshold cycle (Ct) for each PCR
product. Data setswere normalized according to 2 Ct(unspec. ab)Ct(spec. ab).
The fold difference over background obtained for gene regions was
further normalized to the value obtained with a primer pair amplifying
an intergenic region on chromosome 10 where no annotated genes
could be found. For every gene fragment analyzed, each sample was
quantified in duplicate and from 3 independent ChIPs. SEM was
determined for each fold difference above nonimmune control and
intergenic control region.
Construction of maxigenes. To generate the U6–1 maxi TTTT
construct, U6–1 maxigene plasmid DNA [22] was restricted with
EcoN1 at position 66 of the U6 transcribed sequence. Complementary
oligos 59-GTCCCGGGTGTTTTT-39 and 59- CAAAAACACCCGGGA-
39 containing a SmaI restriction site followed by a Pol III termination
sequence were inserted by ligation. For the U6–1 maxi control
construct, primers Mut1 (59-CGTGTCATCCTTGCCACCCGGGACG-
CAG-39) and Mut2 (59-CTGCGTCCCGGGTGGCAAGGATGACACG-
39) were used to delete the five thymidines by PCR mutagenesis using
the QuickChange protocol (Stratagene) as suggested by the manu-
facturer.
Transfection, quantitative PCR, and primer extension. For trans-
fection experiments, HeLa cells were grown to 60%–80% confluency
on a 10 cm dish before the medium was changed to growth medium
containing either 50 nM methyl a-amanitin oleate (a more cell-
permeable derivate of a-amanitin; Merck) or DMSO. 1 lg of each U6
maxigene plasmid (a gift from Gary G. Kunkel [22]) was transfected
with CaPO4 [68]. The medium was replaced by fresh medium
containing 50 nM methyl a-amanitin oleate 16 h later and growth
was continued for 4 h until total RNA was extracted with TRIZOL
(Invitrogen) according to the manufacturer’s recommendation. Total
RNA was briefly exposed to RNase-free DNase I (Ambion) and reverse
transcribed to cDNA using oligo (dT)18 primer or gene-specific
primers and SuperScript III Kit (Invitrogen). cDNA from maxigene
transfected cells was amplified by qPCR and relative expression levels
were determined using the 2DDCt method according to the Stratagene
MX3000 recommendations, using 28S rRNA as calibrator.
For primer extension analysis, HeLa cells were grown to 40%
confluency before CaPO4 cotransfection with 8 lg U6 maxigenes and
5 lg EGFP C3 (Clonetech). After 48 h, total RNA was isolated and
analyzed with the Primer Extension System (Promega) and the
following reverse primers: GFP primer (59-AGCTTGCCG-
TAGGTGGC-39), control primer (59-TGCCACCCGGGACGCAG-39),
TTTTT primer (59-GCAAAAACACCCGGGACG-39), and maxi primer
(59-CGCTTCACGCCTCGAGGG-39), resulting in extension products
of 158, 79, 83, and 109 or 114 bp, respectively. Products were
separated by electrophoresis on 10% polyacrylamide gels containing
7 M urea and exposed to PhosphorImager plates.
Hybrid selection. HeLa cells were grown to 60%–80% confluency
before CaPO4 transfection with 1 lg tRNA
Arg maxigene [69]. After16
h, medium was replaced by DMEM with or without 10 lg/ml a-
amanitin for 3 h, followed by addition of 250 lCi [32P] orthophos-
phate (GE Healthcare) for 6 h before total RNA was extracted with
Trizol. After 5 min denaturation at 70 8C, RNA was allowed to
hybridize with biotinylated oligos complementary to 5S rRNA
together with either U6, U2 [70], or tRNAArg for 30 min in 60%
buffer D containing 5% glycerol [71]. The oligos used were
complementary to positions 88–108 for 5S rRNA, 82–101 for U6
snRNA, 31–45 for U2 snRNA, or 56–76 for tRNAArg. RNA/DNA
hybrids were immunoprecipitated with streptavidin beads for 30 min
followed by 5 washes in 60% buffer D. Immunopurified RNA was
extracted with phenol/chloroform and separated by electrophoresis
on a 10% polyacrylamide gel containing 7 M urea. Band intensities of
RNAs synthesized in the presence of a-amanitin were measured using
a PhosphorImager and normalized to 5S rRNA intensities to account
for IP bead loss and loading differences.
Supporting Information
Figure S1. Genomic Location of the Five Active U6 snRNA Genes
The 107 nucleotide U6 snRNA sequence was aligned to the human
genome with BLAT (BLASTlike alignment tool; UCSC genome
informatics site (http://genome.ucsc.edu/, freeze March 2006, [23,24])
and images of 3 kb surrounding genomic region exported. The
designations of the U6 genes are according to [22].
Found at doi:10.1371/journal.pgen.0030212.sg001 (1.6 MB PDF).
Figure S2. Transcriptional Activity of the U6–1 Surrounding Region
(A) Transcriptional activity of the U6–1 neighbouring gene BC033162
was analyzed by reverse transcription, followed by PCR. Total RNA
from HeLa cells was treated with DNaseI or RNaseA and transcripts
were reverse-transcribed with oligo d(T) or gene-specific primers for
PGK1 and BC033162. The abundance BC033162 mRNA was analyzed
by 27–30 cycles of PCR with primers amplifying a single exon. (B)
Northern Blot with total HeLa RNA with probes specific for U6
snRNA together with probes covering 782 bp of U6 upstream region
on  strand (lane 1) and þ strand (lane 2) as well as probes covering
923 bp of downstream regions of either strand (lane 3) orþ strand
(lane 4) revealed that no transcript derives from the U6–1 locus other
than U6 snRNA. Lane 5, total RNA stained with ethidium bromide;
lane 6, size markers. Asterisks indicate background hybridization to
28S and 18S rRNA.
Found at doi:10.1371/journal.pgen.0030212.sg002 (1.3 MB PDF).
Figure S3. Accumulation Profile of Pol II and Pol III at the U6–1, U6–
7, and U6–8 Promoters
(A, B) Diagrams of the U6–1 and U6–7/U6–8 gene regions, with black
lines specifying the PCR amplicons identified by the central
nucleotide. Boxes represent the position of the DSE. Crosslinked
pemHeLa extracts were used for ChIP with primers amplifying
fragments distributed 1 kb upstream and downstream of each gene.
Antibodies specific for Pol II (4H8 C, D; 8WG16 E, F) and Pol III were
used. X-axis values in (C, E, G) are relative to the U6–1 transcription
start site at positionþ1, whereas transcription start sites in (D, F, H)
are atþ1,302 (U6–7) andþ2,426 (U6–8), relative to an arbitrary point
upstream of U6–7. Data points are placed according to the center
positions of the PCR products along the region. The peak value for
each data set was set to 100% and all data points normalized
accordingly. Error bars represent the SEM of at least three
independent experiments.
Found at doi:10.1371/journal.pgen.0030212.sg003 (84 KB PDF).
Figure S4. Transcriptionally Active Pol II Large Subunit Accumulates
at the U6–1 Promoter
Crosslinked pemHeLa extracts were used for ChIP with Pol II CTD
Ser5 Antibody H14, with primers amplifying fragments distributed
1kb upstream and downstream of U6–1 snRNA gene region. All
values are relative to nonimmune IgG and normalized to an
intergenic control region. Error bars represent the standard
deviation of two independent experiments.
Found at doi:10.1371/journal.pgen.0030212.sg004 (42 KB PDF).
Accession Numbers
Accession numbers for genes mentioned in this paper from the
National Center for Biotechnology Information database (http://www.
ncbi.nlm.nih.gov) are tRNALeu (X04117), tRNATyr (M55612), LDHA
(NM_005566), PGK1 (NM_000291), 5S rRNA (X51545), 28S rRNA
(NR_003287), U2 snRNA (X59360), U1 snRNA (J00318), U6 snRNA
(X07425).
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